skip to main content
Idioma:
previous page 1 Resultados 2 3 next page
Mostrar Somente
Refinado por: Nome da Publicação: Journal Of Clinical Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
11
Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study

Kantarjian, H. ; Giles, F. ; Bhalla, K. ; Pinilla, J. ; Larson, R. A. ; Gattermann, N. ; Ottmann, O. G. ; Gallagher, N. J. ; Baccarani, M. ; leCoutre, P.

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.7029-7029 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
12
To determine the cost-effectiveness of pemetrexed (PEM) compared to current standards of care in 2nd-line advanced non-small cell lung cancer (NSCLC) from the UK National Health Service (NHS) perspective
To determine the cost-effectiveness of pemetrexed (PEM) compared to current standards of care in 2nd-line advanced non-small cell lung cancer (NSCLC) from the UK National Health Service (NHS) perspective
Material Type:
Artigo 		Adicionar ao Meu Espaço

To determine the cost-effectiveness of pemetrexed (PEM) compared to current standards of care in 2nd-line advanced non-small cell lung cancer (NSCLC) from the UK National Health Service (NHS) perspective

Bhalla, S. ; Hibbert, C. ; Watkins, J. ; Beard, S. ; Cetty, M. ; Arellano, J.

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.6540-6540 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
13
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against unmutated or mutant Bcr-Abl-expressing human leukemia cells
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against unmutated or mutant Bcr-Abl-expressing human leukemia cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against unmutated or mutant Bcr-Abl-expressing human leukemia cells

Fiskus, W. ; Pranpat, M. ; Balasis, M. ; Atadja, P. ; Manley, P. ; Giles, F. ; Bhalla, K.

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.6592-6592 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
14
A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib

Giles, F. J. ; le Coutre, P. ; Bhalla, K. ; Rosti, G. ; Ossenkoppele, G. ; Alimena, G. ; Weitzman, A. ; Zheng, M. ; Kantarjian, H.

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.7038-7038 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
15
Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
Material Type:
Artigo 		Adicionar ao Meu Espaço

Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results

Kantarjian, H. M. ; Giles, F. J. ; Hochhaus, A. ; Bhalla, K. N. ; Ossenkoppele, G. J. ; Gattermann, N. ; Haque, A. ; Gallagher, N. ; Castagnetti, F. ; le Coutre, P.

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.7010-7010 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
16
Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)
Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)

Jabbour, E. ; Hochhaus, A. ; le Coutre, P. ; Rosti, G. ; Bhalla, K. N. ; Haque, A. ; Gallagher, N. ; Giles, F. J. ; Cortes, J. E. ; Kantarjian, H. M.

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.7063-7063 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
17
Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study
Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study

Abruzzese, E. ; Alimena, G. ; le Coutre, P. ; Bhalla, K. N. ; Ossenkoppele, G. J. ; Haque, A. ; Gallagher, N. ; Kantarjian, H. M. ; Giles, F. J.

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.7055-7055 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
18
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC)
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC)

Choueiri, T. K. ; Vaziri, S. A. ; Rini, B. I. ; Elson, P. ; Bhalla, I. ; Jaeger, E. ; Weinberg, V. ; Waldman, F. M. ; Zhou, M. ; Bukowski, R. M. ; Ganapathi, R.

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5012-5012 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
19
Inhibition of histone deacetylase (HDAC) 6 sensitizes human leukemia and breast cancer cells to antagonists of heat shock protein (hsp) 90 and/or bortezomib (BZ)
Inhibition of histone deacetylase (HDAC) 6 sensitizes human leukemia and breast cancer cells to antagonists of heat shock protein (hsp) 90 and/or bortezomib (BZ)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Inhibition of histone deacetylase (HDAC) 6 sensitizes human leukemia and breast cancer cells to antagonists of heat shock protein (hsp) 90 and/or bortezomib (BZ)

Bhalla, K. N. ; Bali, P. ; Balasis, M. ; Fiskus, W. ; Pranpat, M. ; Rocha, K. ; Rao, R. M. ; Kumaraswamy, S. ; Atadja, P.

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.13039-13039 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
20
Do the published toxicity data from clinical trials in oncology give the full picture? An example using pemetrexed and docetaxel
Do the published toxicity data from clinical trials in oncology give the full picture? An example using pemetrexed and docetaxel
Material Type:
Artigo 		Adicionar ao Meu Espaço

Do the published toxicity data from clinical trials in oncology give the full picture? An example using pemetrexed and docetaxel

Stynes, G. ; Gatzemeier, U. ; Thatcher, N. ; Bhalla, S. ; Aristides, M. ; Leschinger, M. ; Tilden, D.

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.8188-8188 [Periódico revisado por pares]

Sem texto completo

Citações Citado por
previous page 1 Resultados 2 3 next page

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.